PROFESSIONAL EDITION

The largest community of pharma leaders

Immunomic Therapeutics Appoints Andrew Eisen, M.D., Ph.D. as VP, Clinical Development

ROCKVILLE, Md.–(BUSINESS WIRE)–Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today the appointment of Andrew Eisen, M.D., Ph.D. as VP, Clinical Development. Dr. Eisen is a translational medicine and clinical development specialist with over 20 years of experience in the biotech and pharma sectors. Prior to joining ITI, Dr. Eisen held executive-level roles in translational medicine for Rexahn Pharmaceuticals, Acorda Therapeutics, Eisai On

 

 

 

http://www.businesswire.com/news/home/20190712005087/en/Immunomic-Therapeutics-Appoints-Andrew-Eisen-M.D.-Ph.D.

 

Recent Articles